ArticleJournal for immunotherapy of cancer2025
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic cancer vaccines: development, challenges, and future perspectives.Acta pharmacologica Sinica · 2026Review
- Therapeutic cancer vaccines in pancreatic cancer.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA chemoimmunotherapy regimen consisting of a novel Wilms' tumor 1 (WT1) peptide-pulsed dendritic cell (WT1-DC) vaccine and multiagent chemotherapy was observed to modulate the tumor microenvironment (TME) to an immunostimulatory state, resulting in conversion surgery in seven out of nine patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC).
methodsUnderstanding WT1-specific immunity and the tumor mutational burden is important for predicting the efficacy of WT1-targeted chemoimmunotherapy. Therefore, the memory CD8+T cell subpopulations in WT1-specific cytotoxic T lymphocytes (WT1-CTLs), titers of antibodies against the WT1 epitopes, infiltration of CD103+tissue-resident memory T cells and CD20+cells in the pancreatic TME, gene mutations in plasma circulating tumor DNA (ctDNA) obtained via liquid biopsy, and PDAC cell characteristics were evaluated.
resultsPrior to treatment, patients with a relatively low number of WT1-specific CD8+naive T (Tn) cells, high levels of WT1-specific IgM antibodies, no mutations in any key genes (
conclusionsIn patients with UR-PDAC who exhibited spontaneous activation of WT1-specific cellular and humoral immunity prior to treatment, endogenous WT1-specific CD8+Tn cells were engineered into WT1-specific memory CD8+cells via WT1-targeted chemoimmunotherapy, resulting in superior therapeutic effects. WT1-targeted chemoimmunotherapy also induced neoantigen-specific immune responses via epitope spreading, leading to the elimination of neoantigen-expressing PDAC cells and favorable clinical outcomes. TRIAL REGISTRATION NUMBER: jRCTc030190195.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.